Pediatric Medulloblastoma Project

Medulloblastoma (MB) is the most common malignant pediatric brain tumor. It is diagnosed most often between the ages of three and eight, but can occur at any age. Histopathological and molecular stratification have distinguished between four core subgroups: SHH, WNT, Group C and Group D. 

The SHH and WNT groups are better defined and have better prognosis. Group C and D etiology on the other hand is poorly defined and the prognosis for these groups is considered the worst.

Our aim is to shed light on the etiology of group C and D medulloblastoma poor prognosis and provide tools to discover individualized treatments for medulloblastoma patients with worst prognosis.

To this we investigate the role of recently discovered regulatory Long Non Coding RNAs factors.